RPRX Stock Overview
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.
Royalty Pharma plc Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$42.98|
|52 Week High||US$44.75|
|52 Week Low||US$36.15|
|1 Month Change||0.51%|
|3 Month Change||1.56%|
|1 Year Change||2.60%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-3.42%|
Recent News & Updates
The Price Is Right For Royalty Pharma plc (NASDAQ:RPRX)Apr 25
Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To US$0.19Jan 25
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At US$0.19Jan 11
Key Things To Watch Out For If You Are After Royalty Pharma plc's (NASDAQ:RPRX) 1.6% DividendMar 08
Do Insiders Own Lots Of Shares In Royalty Pharma plc (NASDAQ:RPRX)?Feb 01
Are Royalty Pharma's (NASDAQ:RPRX) Statutory Earnings A Good Reflection Of Its Earnings Potential?Dec 28
Are Investors Undervaluing Royalty Pharma plc (NASDAQ:RPRX) By 40%?Nov 30
|RPRX||US Pharmaceuticals||US Market|
Return vs Industry: RPRX underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: RPRX exceeded the US Market which returned -18.5% over the past year.
|RPRX Average Weekly Movement||2.8%|
|Pharmaceuticals Industry Average Movement||11.0%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: RPRX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: RPRX's weekly volatility (3%) has been stable over the past year.
About the Company
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Royalty Pharma plc Fundamentals Summary
|RPRX fundamental statistics|
Is RPRX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RPRX income statement (TTM)|
|Cost of Revenue||US$861.90m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||1.15|
|Net Profit Margin||22.55%|
How did RPRX perform over the long term?See historical performance and comparison